A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)

NCT04143802 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety of the experimental drug LY3437943 in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind basic-science study

Participants 72 people

Who can join Ages 20–70 · all sexes

Timeline Started 2019-12 · est. completion 2020-12

Where 4 sites · United States

What this study is testing ClinicalTrials.gov NCT04143802 ↗

Description as written by the study sponsor.

The main purpose of this study is to learn about the side effects of LY3437943 when given to participants with type 2 diabetes. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive injections of LY3437943, dulaglutide, or placebo given just under the skin. For each participant, the study will last up to about 5 months and will include 16 visits to the study center.

Treatments tested

LY3437943 Drug

Administered SC
Dulaglutide also known as LY2189265 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04143802 ↗